Medications

Epkinly granted accelerated FDA approval for lymphoma treatment

The U.S. Food and Drug Administration has granted accelerated approval for Genmab's Epkinly (epcoritamab-bysp) for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), including DLBCL arising from indolent lymphoma, ...

page 3 from 40